FDA accepts PolyPid's D-PLEX100 NDA with priority review
Tweet Send to a Friend
PolyPid Ltd. (NASDAQ: PYPD) announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


